On-Demand Versus Daily Sildenafil for Premature Ejaculation

In 1990, Fein reported on a small group (N

• Misusing sildenafil for PE can cause serious health risks.
• The drug's primary purpose is erectile dysfunction.
• Off-label use for PE should be supervised by a doctor.
• Performance anxiety often exacerbates PE.
• Proper medication adherence improves results.
• Natural remedies lack strong scientific support.
• Combining drugs without guidance is dangerous.
• Behavioral adjustments can sometimes eliminate PE.
• It is vital to address both physical and psychological aspects.
• Clinical trials explore sildenafil's role in PE management.
• Open communication with a healthcare professional is key.

= 8) of patients

with PE who used vasoactive

• Sildenafil's role in PE is still under research.
• Off-label use requires informed consent.
• Behavioral techniques are first-line in many cases.
• The impact of psychological health on PE should not be ignored.
• Educating patients on realistic expectations is important.
• Sometimes, medication just masks underlying issues.
• Regular sexual activity can decrease PE severity.
• Consulting a urologist is recommended for persistent PE.
• Combining medication with therapy often improves outcomes.
• Delaying ejaculation involves both physical and mental strategies.
• Support and understanding enhance treatment adherence.

intracavernosal pharmacotherapy (mixture of

References (14)

A crossover study of 31 potent men with lifelong PE found sildenafil treatment to be associated with a significantly higher IELT and higher sexual satisfaction score than any other therapy including the use of any one of a variety of SSRIs and the use of the squeezepause method [1,86]. Sildenafil was deemed “decidedly the most effective” and was recommended as a valid alternative to the use of SSRIs in the treatment of PE. Conversely, the presence of concomitant PE did not impair patient satisfaction with their improved erections, when men were treated with PDE5 inhibitors for their ED [87]. A recent review found that of five studies, three have concluded that the use of PDE5 inhibitors was helpful, even superior, in treating PE, while two placebo-controlled studies found no such improvement [88]. The single study, which used objective, double-blinded, placebo-controlled measures, found no improvement in PE following PDE5 inhibitors in men who did not also have associated ED [83].

The pause-squeeze technique

In a placebo-controlled trial in 84 patients, sildenafil proved ineffective, either alone or in combination with topical therapy, in the treatment of acquired PE [2]. PDE5 inhibitors may exert a secondary benefit for patients with PE when they (i) allow for a sustained penile erection, even after ejaculation; (ii) facilitate a second intercourse after the initial ejaculation, which is often less prone to PE; and/or (iii) help the patient to overcome performance anxiety, which often exacerbates PE [83,89]. However, it is deemed unlikely that PDE5 inhibitors have a significant role in the treatment of PE—with the exception of men with acquired PE secondary to ED [1]. The use of ICI for “treatment” of PE is not supported by a large body of peer-reviewed literature, and is infrequently used in clinical practice. However, ICI has been used as a strategy in certain cases to allow men with PE to maintain their erections and continue satisfactory sexual intercourse despite rapid ejaculation. phentolamine mesylate [1.0 mg/mL] and

• Premature ejaculation affects about 30% of men.
• Psychological factors often contribute to PE.
• Behavioral therapies can help manage PE.
• Topical anesthetics are alternative treatments for PE.
• SSRI antidepressants are commonly prescribed for PE.
• Combining sildenafil with PE drugs requires care.
• Lifestyle changes like exercise may improve PE.
• Stress and anxiety can trigger premature ejaculation.
• Delay techniques include the stop-start method.
• Medical treatments should be personalized for each patient.
• Education about sexual response can reduce PE.

papaverine hydrochloride [30 mg/mL])

to address their PE [90].